Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for deadly brain cancer: triple-drug attack shows promise

NCT ID NCT07523737

Recruiting now Disease control Sponsor: Beijing Tongren Hospital Source: ClinicalTrials.gov ↗

First seen Apr 25, 2026 · Last updated Apr 25, 2026

Summary

This study tests a combination of three drugs (pomalidomide, an anti-PD-1 antibody, and selinexor) in people whose primary central nervous system lymphoma has come back or stopped responding to treatment. About 43 adults aged 18-75 will receive this therapy to see if it can shrink tumors and improve survival. The goal is to offer a new option for a condition that currently has very few effective treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Tongren Hospital, Capital Medical University

    RECRUITING

    Beijing, Beijing Municipality, 100730, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)